Drug Detail:Erenumab (Erenumab [ e-ren-ue-mab ])
Drug Class: CGRP inhibitors
Usual Adult Dose for Migraine Prophylaxis
70 mg subcutaneously once a month
- Some patients may benefit from 140 mg subcutaneously once a month
Use: For the preventative treatment of migraine.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended
Dose Adjustments
Elderly: No specific recommendations, however, in general, dose selection should be cautious, generally starting at the low end of the dosing range.
Precautions
CONTRAINDICATIONS:
- Serious hypersensitivity to the active substance or any product excipients; anaphylaxis and angioedema have occurred.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For subcutaneous use only
- Administer subcutaneously in the abdomen, thigh, or upper arm; do not inject into areas where the skin is tender, bruised, red, or hard
- Patients/caregivers should be trained to properly administer using the single-dose prefilled autoinjector or single-dose prefilled syringe
Storage requirements:
- Store refrigerated at 2C to 8C (36F to 46F) in the original container to protect from light; do not freeze
- Once removed from refrigerator, keep at room temperature (up to 25C [77F]) in the original carton and use within 7 days; discard unused product kept at room temperature for more than 7 days
Reconstitution/preparation techniques:
- Prior to administration, allow drug to sit at room temperature for at least 30 minutes (protect from direct sunlight); do not warm by using a heat source such as hot water or a microwave
- Do not shake
General:
- The needle shield within the white cap of the prefilled autoinjector and gray needle cap of the prefilled syringe contain dry natural rubber (a derivative of latex); this may cause allergic reactions in individuals sensitive to latex.
- In clinical trials, doses of 70 mg and 140 mg were compared to placebo; drug-treatment with both doses demonstrated statistically significant improvements compared to placebo; additionally, patients receiving 140 mg/month showed some improvement over the 70 mg/month dose, although doses were not titrated up nor directly compared.
Monitoring:
- Monitor for severe constipation
- Monitor for hypertension
Patient advice:
- Patients should be instructed to read the US FDA-approved Patient Information and Instructions for Use.
- Patients should receive instruction on proper subcutaneous administration technique.
- Patients should be instructed to seek immediate medical attention if they experience any symptoms of a serious or severe hypersensitivity reaction, severe constipation, and/or hypertension or worsening of preexisting hypertension.
Frequently asked questions
- What are the new drugs for the treatment of migraines?
- Emgality vs Aimovig - how do they compare?
- Ajovy vs Aimovig: What's the difference between them?
- How long does it take for Aimovig to start working?
- Does Aimovig cause weight gain or loss?
- Why does Aimovig cause constipation?
- How is Vyepti different from Aimovig?
- What is the cost of the migraine drug Ajovy?
- How long does Aimovig last in your system?
- What is the mechanism of action of Aimovig?
- Can you drink alcohol with Aimovig?
- Can Aimovig cause hair loss (alopecia)?
- How do you use the Aimovig autoinjector?
- How do you inject Aimovig?
- What type of drug is Ajovy?
